# A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma

> **NCT00743496** · PHASE1 · COMPLETED · sponsor: **St. Jude Children's Research Hospital** · enrollment: 50 (actual)

## Conditions studied

- Neuroblastoma
- Melanoma
- Osteosarcoma
- Ewing Sarcoma

## Interventions

- **BIOLOGICAL:** Anti-GD2 antibody

## Key facts

- **NCT ID:** NCT00743496
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10-08
- **Primary completion:** 2014-04-01
- **Final completion:** 2014-04-18
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2017-08-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00743496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00743496, "A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00743496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*